The newly-released Public Summary Document shows the PBAC acknowledging the efficacy and strong support for the listing of Sanofi's DUPIXENT (dupilumab) for severe atopic dermatitis but also its focus on the potential mix of new and continuing patients. …
Latest Video
New Stories
-
The COVID-19 vaccine manufacturing and supply deals
August 7, 2020 - - Latest News -
Greg Hunt moves to extend industry agreements
August 7, 2020 - - Latest News -
CSL says it is now 'exploring ways' to manufacture another vaccine
August 7, 2020 - - Latest News -
Goldman Sachs: US will be first because it has invested the most
August 6, 2020 - - Latest News -
What is the strategy? Is there a strategy?
August 6, 2020 - - Comment -
Neurohack brainstorms solutions for young people with SMA
August 6, 2020 - - Latest News -
Ventolin with dose counter makes it to the PBS
August 6, 2020 - - Latest News